Validation of a deep learning-based AI model for breast cancer risk stratification in postmenopausal ER+/HER2-breast cancer patients
The Stratipath AI model performs similarly to the NHG system. Further prospective validation of the clinical benefits of differentiating Stratipath risk groups 2 and 3 in treatment strategies would be valuable.
Authors
- Maj‐Britt Jensen (ORCID: https://orcid.org/0000-0001-5348-3040)
- Sandra Sinius Pouplier (ORCID: https://orcid.org/0000-0002-2625-7440)
- Mattias Rantalainen (ORCID: https://orcid.org/0000-0002-7740-2986)
- Anne‐Vibeke Lænkholm (ORCID: https://orcid.org/0000-0003-2166-8686)
- Pekka Ruusuvuori (ORCID: https://orcid.org/0000-0001-9086-9591)
- Abhinav Sharma (ORCID: https://orcid.org/0000-0002-6768-0296)
- Johan Hartman
- Bent Ejlertsen
Institutions
- University of Turku (FI)
- Copenhagen University Hospital (DK)
- Karolinska Institutet (SE)
- Zealand University Hospital (DK)
- Karolinska Development (Sweden) (SE)
- Danish Breast Cancer Cooperative Group (DK)
Publication Details
- Journal
- The Breast
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1016/j.breast.2025.104671
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00